摘要
Background It is internationally accepted that in drug-naieve individualswith hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection, chronic hepatitisC should be treated first if the CD4 cell count does not require the initiation of anti-retroviraltherapy. Present paper evaluated the clinical effect and side-effect of interferon-α (IFN-α) andribavirin ( RBV) combination therapy for Chinese patients with HCV-HIV co-infection, and comparedwith them for HIV infection alone. Methods Ten patients with HCV-HIV and 17 patients with HCVreceived 5 million unit IFNα-2b every other day intramuscularly, and 300 mg RBV triple daily byoral. Dynamic observations were made for HCV RNA and HIV RNA loads, CD4^+ and CDS^+ T lymphocytecounts, liver function and blood cell measurement, and the medicine side-effects. Results After12-week and 24-week treatments of IFN-α and RBV combination therapy, mean HCV RNA levels reduced 1.14 logs and 1. 56 logs from the baseline at week 0 in HCV-HIV co-infection, and reduced 1. 48 logsand 1. 75 logs in HCV infection, respectively. The HIV RNA levels decreased 1. 22 logs and 1. 32logs from the base line; however, there were no obvious different changes at T lymphocyte counts ofHCV-HIV and HCV patients through 24-week treatments. Whole 27 patients showed satisfactorybiochemical response to therapy. There were some mild or mediate influence-like symptoms, intestinaluncomfortable and depressed blood cell counts in early stage of the treatments. No neuropsychiatricand auto-immune disorders were found. Conclusions IFN-α and RBV combination therapy had similaranti-HCV effects during 24-week treatment for HCV-HIV and HCV infected Chinese patients, and someanti-HIV effect. There were no obvious different biochemical responses and side-effects between twogroups above.
Background It is internationally accepted that in drug-naieve individualswith hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection, chronic hepatitisC should be treated first if the CD4 cell count does not require the initiation of anti-retroviraltherapy. Present paper evaluated the clinical effect and side-effect of interferon-α (IFN-α) andribavirin ( RBV) combination therapy for Chinese patients with HCV-HIV co-infection, and comparedwith them for HIV infection alone. Methods Ten patients with HCV-HIV and 17 patients with HCVreceived 5 million unit IFNα-2b every other day intramuscularly, and 300 mg RBV triple daily byoral. Dynamic observations were made for HCV RNA and HIV RNA loads, CD4^+ and CDS^+ T lymphocytecounts, liver function and blood cell measurement, and the medicine side-effects. Results After12-week and 24-week treatments of IFN-α and RBV combination therapy, mean HCV RNA levels reduced 1.14 logs and 1. 56 logs from the baseline at week 0 in HCV-HIV co-infection, and reduced 1. 48 logsand 1. 75 logs in HCV infection, respectively. The HIV RNA levels decreased 1. 22 logs and 1. 32logs from the base line; however, there were no obvious different changes at T lymphocyte counts ofHCV-HIV and HCV patients through 24-week treatments. Whole 27 patients showed satisfactorybiochemical response to therapy. There were some mild or mediate influence-like symptoms, intestinaluncomfortable and depressed blood cell counts in early stage of the treatments. No neuropsychiatricand auto-immune disorders were found. Conclusions IFN-α and RBV combination therapy had similaranti-HCV effects during 24-week treatment for HCV-HIV and HCV infected Chinese patients, and someanti-HIV effect. There were no obvious different biochemical responses and side-effects between twogroups above.
基金
ThisstudywassupportedbyagrantfromAIDSResearchFoundationofChineseMinistryofHealth(No.WA2003-15).
